Contribution of cytogenetics to the management of poorly differentiated sarcomas

Julia A. Bridge

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Sarcomas constitute a heterogeneous group of rare tumors that in recent years have been shown by cytogenetic analysis to have a remarkably high incidence of specific and primary alterations. These genetic alterations not only have guided molecular studies in establishing the underlying genes involved, thereby yielding important pathogenetic information, but have also provided clinicians with a valuable tool to add to their diagnostic armamentarium. The addition of molecular cytogenetic (fluorescence in situ hybridization [FISH]) and molecular approaches (reverse transcriptase-polymerase chain reaction [RT-PCR]) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances and/or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues. Poorly differentiated sarcomas represent a significant challenge to the pathologist as these neoplasms lack an identifiable hematoxylin and eosin-stained phenotype and often have lost diagnostic immunohistochemical or ultrastructural features as well. In contrast, primary cytogenetic changes and associated molecular events such as the 11;22 translocation in Ewing sarcoma are retained as a given tumor metastasizes or becomes less differentiated, as their presence appears to be vital for sustaining neoplastic transformation. Consequently, demonstration of characteristic, tumor-specific chromosomal aberrations is especially useful in the management of poorly differentiated sarcomas.

Original languageEnglish (US)
Pages (from-to)63-71
Number of pages9
JournalUltrastructural Pathology
Volume32
Issue number2
DOIs
StatePublished - Apr 1 2008

Fingerprint

Cytogenetics
Sarcoma
Tumors
cancer
tumors
Neoplasms
Polymerase chain reaction
Aberrations
Formaldehyde
Paraffins
Ewing's Sarcoma
Cytogenetic Analysis
Demonstrations
Hematoxylin
Eosine Yellowish-(YS)
Genes
polymerase chain reaction
neoplasms
Reverse Transcriptase Polymerase Chain Reaction
Fluorescence

Keywords

  • Cytogenetics
  • FISH
  • Karyotype
  • Poorly differentiated sarcoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Structural Biology

Cite this

Contribution of cytogenetics to the management of poorly differentiated sarcomas. / Bridge, Julia A.

In: Ultrastructural Pathology, Vol. 32, No. 2, 01.04.2008, p. 63-71.

Research output: Contribution to journalArticle

@article{93ae06a43dfc4cea82726936b1d8f83d,
title = "Contribution of cytogenetics to the management of poorly differentiated sarcomas",
abstract = "Sarcomas constitute a heterogeneous group of rare tumors that in recent years have been shown by cytogenetic analysis to have a remarkably high incidence of specific and primary alterations. These genetic alterations not only have guided molecular studies in establishing the underlying genes involved, thereby yielding important pathogenetic information, but have also provided clinicians with a valuable tool to add to their diagnostic armamentarium. The addition of molecular cytogenetic (fluorescence in situ hybridization [FISH]) and molecular approaches (reverse transcriptase-polymerase chain reaction [RT-PCR]) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances and/or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues. Poorly differentiated sarcomas represent a significant challenge to the pathologist as these neoplasms lack an identifiable hematoxylin and eosin-stained phenotype and often have lost diagnostic immunohistochemical or ultrastructural features as well. In contrast, primary cytogenetic changes and associated molecular events such as the 11;22 translocation in Ewing sarcoma are retained as a given tumor metastasizes or becomes less differentiated, as their presence appears to be vital for sustaining neoplastic transformation. Consequently, demonstration of characteristic, tumor-specific chromosomal aberrations is especially useful in the management of poorly differentiated sarcomas.",
keywords = "Cytogenetics, FISH, Karyotype, Poorly differentiated sarcoma",
author = "Bridge, {Julia A.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1080/01913120801897141",
language = "English (US)",
volume = "32",
pages = "63--71",
journal = "Ultrastructural Pathology",
issn = "0191-3123",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Contribution of cytogenetics to the management of poorly differentiated sarcomas

AU - Bridge, Julia A.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Sarcomas constitute a heterogeneous group of rare tumors that in recent years have been shown by cytogenetic analysis to have a remarkably high incidence of specific and primary alterations. These genetic alterations not only have guided molecular studies in establishing the underlying genes involved, thereby yielding important pathogenetic information, but have also provided clinicians with a valuable tool to add to their diagnostic armamentarium. The addition of molecular cytogenetic (fluorescence in situ hybridization [FISH]) and molecular approaches (reverse transcriptase-polymerase chain reaction [RT-PCR]) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances and/or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues. Poorly differentiated sarcomas represent a significant challenge to the pathologist as these neoplasms lack an identifiable hematoxylin and eosin-stained phenotype and often have lost diagnostic immunohistochemical or ultrastructural features as well. In contrast, primary cytogenetic changes and associated molecular events such as the 11;22 translocation in Ewing sarcoma are retained as a given tumor metastasizes or becomes less differentiated, as their presence appears to be vital for sustaining neoplastic transformation. Consequently, demonstration of characteristic, tumor-specific chromosomal aberrations is especially useful in the management of poorly differentiated sarcomas.

AB - Sarcomas constitute a heterogeneous group of rare tumors that in recent years have been shown by cytogenetic analysis to have a remarkably high incidence of specific and primary alterations. These genetic alterations not only have guided molecular studies in establishing the underlying genes involved, thereby yielding important pathogenetic information, but have also provided clinicians with a valuable tool to add to their diagnostic armamentarium. The addition of molecular cytogenetic (fluorescence in situ hybridization [FISH]) and molecular approaches (reverse transcriptase-polymerase chain reaction [RT-PCR]) has further enhanced the sensitivity and accuracy of detecting nonrandom chromosomal imbalances and/or structural rearrangements in sarcomas, including assessment in formalin-fixed, paraffin-embedded tissues. Poorly differentiated sarcomas represent a significant challenge to the pathologist as these neoplasms lack an identifiable hematoxylin and eosin-stained phenotype and often have lost diagnostic immunohistochemical or ultrastructural features as well. In contrast, primary cytogenetic changes and associated molecular events such as the 11;22 translocation in Ewing sarcoma are retained as a given tumor metastasizes or becomes less differentiated, as their presence appears to be vital for sustaining neoplastic transformation. Consequently, demonstration of characteristic, tumor-specific chromosomal aberrations is especially useful in the management of poorly differentiated sarcomas.

KW - Cytogenetics

KW - FISH

KW - Karyotype

KW - Poorly differentiated sarcoma

UR - http://www.scopus.com/inward/record.url?scp=43049138862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049138862&partnerID=8YFLogxK

U2 - 10.1080/01913120801897141

DO - 10.1080/01913120801897141

M3 - Article

C2 - 18446669

AN - SCOPUS:43049138862

VL - 32

SP - 63

EP - 71

JO - Ultrastructural Pathology

JF - Ultrastructural Pathology

SN - 0191-3123

IS - 2

ER -